The rational design and optimization of therapeutic antibodies is increasingly being improved with high-resolution structural data and machine learning (ML) frameworks that can model complex antibody-antigen interactions. Recent research highlights a movement toward the use of large-scale, curated s
Recent studies highlighttheleveraging of distinct immunological functions of IgE to augment or replace conventional IgG1-based therapies, particularly for treatment-resistant solid tumors. Building on growing evidence of IgE’s pro-inflammatory, tumor-reprogramming capabilities, novel hy
Natural killer (NK) cell-based therapies are rapidly gaining traction as immunotherapies, offering advantages over traditional T cell-based approaches, particularly in safety and specificity. While T cell engagers (TCEs) have demonstrated clinical efficacy, their use is limited by toxicities such as
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow, often resulting in anemia, bone lesions, hypercalcemia, and renal dysfunction.
Over the past decade, the Fc domain of antibodies was thought of as a passive structural region appreciated primarily for its interaction with Fcγ receptors (FcγRs) and the neonatal Fc receptor (FcRn). Now, the Fc region is a major focus of innovation, enabling fine-tuned control over immune engag
The fight against Alzheimer’s disease (AD) has entered a new era, driven by major advances in immunotherapy. Monoclonal antibodies (mAbs) targeting hallmark proteins such as amyloid-beta and tau, have dominated recent research, clinical trials, and regulatory approvals. However, while new therapies show potential, the field faces critical questions about efficacy, safety, and scientific validity.
As antibody-based therapies continue to advance the treatment of cancer, autoimmune diseases, and infectious disorders, a parallel challenge has emerged: managing the immune system’s response to these biologics.
Patients with ovarian cancer are often diagnosed late and prone to frequent relapse. Despite advances in surgery and chemotherapy, treatment resistance can leave clinicians with limited options. But a new generation of antibody-based therapies is offering renewed hope, combining precision targeting with immune activation and potent cytotoxic delivery.
Just this week, Merida Biosciences emerged from stealth with a $121 million Series A financing to develop a new class of precision therapeutics that eliminate pathogenic antibodies in autoimmune and allergic diseases. With programs targeting Graves’ disease, primary membranous nephropathy, and seve
Affinity maturation is a fundamental process in the adaptive immune response that results in the selection of B cells producing antibodies with increased binding affinity for their target antigen. This process occurs in germinal centers and is driven by somatic hypermutation and selection pressures.
The therapeutic potential of monoclonal antibodies (mAbs) has expanded dramatically over the past two decades, driven not only by advances in target discovery but also by innovations in antibody engineering. Among these, the engineering of the fragment crystallizable (Fc) domain has emerged as a pow
Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).
You can also contact us on the Scientist and Science Exchange marketplaces.
